Sadhana Nitro Chem Q3 FY26: Sales Crash 74%, ₹25 Cr Quarterly Loss, Debt ₹258 Cr – Can This 0.83x Book Chemical Stock Survive?
1. At a Glance – This Is Not a Drill
Sadhana Nitro Chem Ltd is currently trading at ₹6.31 with a market cap of ₹208 crore. Sounds cheap? Wait. The latest quarterly sales are just ₹9.76 crore, down a brutal 73.7% YoY. Quarterly PAT? A negative ₹25.14 crore. EPS for Q3 FY26 stands at ₹-0.76. OPM has collapsed to -156%.
Debt stands at ₹258 crore while total assets are ₹616 crore (latest consolidated Sep 2025). Interest coverage is negative at -1.40. Debtor days? A leisurely 270 days. Promoter holding? Slashed to 29.97% in Dec 2025 from above 74% two years ago.
Return over 1 year: -78%. Return over 3 years: -55%.
And yet — it trades at 0.83x book value. Dividend yield shows 1.58%.
So the real question is — is this a deep value chemical play… or a chemistry experiment gone wrong?
2. Introduction – From Export House to Financial House on Fire?
Incorporated in 1973, Sadhana Nitro Chem calls itself a government-recognized 2-Star Golden Export House. ISO certified. Exports to Belgium, USA, UK, Japan, Switzerland — the whole world map.
On paper, this is a specialty chemical manufacturer serving aerospace, pharma, agro, dyes, plastics — everything that sounds sophisticated.
But numbers don’t care about certificates.
Revenue for TTM stands at ₹90 crore. PAT for TTM? ₹-49 crore. OPM TTM: -19%.
The company once posted decent profitability in FY19–FY24. Then FY26 Q3 arrives and wipes out investor confidence like acetone on nail polish.
Promoter holding crashed from 74% (Mar 2023) to 29.97% (Dec 2025). Public holding has ballooned to nearly 70%.
You tell me — when promoters reduce stake so sharply, is it portfolio diversification… or risk management?
Let’s dig deeper.
3. Business Model – WTF Do They Even Do?
Sadhana Nitro Chem manufactures chemical intermediates.
Main products:
Meta Amino Phenol (46.32% of FY24 sales)
ODB2 / SND-27 (36.64%)
Para Amino Phenol (12.75%)
Nitrobenzene (0.35%)
Applications include:
Optical brightening agents (paper industry)
Dyes & pigments
Pharmaceuticals (including Paracetamol)
Epoxy hardeners
Agro chemicals
They expanded ODB2 capacity from 550 TPA to 2200 TPA. Current utilization: 50%.
They improved PAP quality by eliminating impurities. Introduced paracetamol.
They acquired Calchem Industries in Jan 2025. Then in Q1 FY26, they sold the subsidiary for ₹13 crore.
Acquisition → Subsidiary → Sale → Losses → Rights Issue.
Is this strategy… or speed dating with assets?
Also — they have a Belgium subsidiary, Anuchem B.V.B.A.
Exports form ~38% of FY24 revenue.
So business exists. Products exist. Demand exists.
